




FIG. 2B

FIG. 2A



TITLE: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING
ANTISENSE OLIGONUCLEOTIDES

INVENTORS NAME: Larry Wayne Oberley et al.

DOCKET NO.: 875.042US1

4/11




FIG. 4

TITLE: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING
ANTISENSE OLIGONUCLEOTIDES

INVENTORS NAME: Larry Wayne Oberley et al.

DOCKET NO.: 875.042US1

5/11




FIG. 5




FIG. 6

TITLE: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING
ANTISENSE OLIGONUCLEOTIDES

INVENTORS NAME: Larry Wayne Oberley et al.

DOCKET NO.: 875,042US1

7/11




FIG. 7B

FIG. 7A

TITLE: REDUCTION OF ANTIOXIDANT ENZYME LEVELS IN TUMOR CELLS USING
 ANTISENSE OLIGONUCLEOTIDES

INVENTORS NAME: Larry Wayne Oberley et al.

DOCKET NO.: 875.042US1

8/11





FIG. 8

2011112222660

| Group | Disease Free Mice (Day 316) | Number of Mice Living |
|---------------------|--------------------------------|--------------------------|
| MCF-7 Control | 25% (1/4) | (2/4) |
| Lipofectin only | 25% (1/4) | (1/4) |
| Antisense MnSOD ODN | 75% (3/4) | (3/4) |
| Mismatch MnSOD ODN | 0% (0/4) | (0/4) |
| Scrambled MnSOD ODN | 50% (2/4) | (2/4) |
| Sense MnSOD ODN | 25% (1/4) | (1/4) |


FIG. 9

FIG. 10B



Effectene

FIG. 10A



Control

Antisense
MnSOD




FIG. 10C

*500 cells/well




FIG. 11